Compare RGP & RZLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RGP | RZLT |
|---|---|---|
| Founded | 1996 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 149.5M | 420.8M |
| IPO Year | 2000 | 2011 |
| Metric | RGP | RZLT |
|---|---|---|
| Price | $3.84 | $4.02 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 6 |
| Target Price | $7.00 | ★ $9.67 |
| AVG Volume (30 Days) | 279.1K | ★ 1.1M |
| Earning Date | 04-08-2026 | 05-13-2026 |
| Dividend Yield | ★ 6.85% | N/A |
| EPS Growth | ★ 79.14 | 26.32 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $452,006,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.06 | $1.07 |
| 52 Week High | $5.37 | $11.46 |
| Indicator | RGP | RZLT |
|---|---|---|
| Relative Strength Index (RSI) | 42.78 | 42.68 |
| Support Level | $3.81 | $2.91 |
| Resistance Level | $4.24 | $5.36 |
| Average True Range (ATR) | 0.15 | 0.24 |
| MACD | -0.01 | -0.02 |
| Stochastic Oscillator | 24.24 | 47.64 |
Resources Connection Inc is a professional services firm. Its segments include On-Demand Talent provides businesses with a go-to source for bringing in experts when its needed, serving the office of the CFO; Consulting drives transformation across people, processes and technology across domain areas including finance, technology and digital, risk and compliance and operational performance; Europe & Asia Pacific offers both on-demand and consulting services to clients throughout Europe and Asia Pacific; Outsourced Services; and Sitrick. It derives the majority of revenue from On-Demand Talent segment. Geographically, it operates in United States and internationally.
Rezolute Inc is a clinical-stage biopharmaceutical company focused on developing therapies for rare and metabolic diseases. The company aims to address unmet medical needs in conditions like congenital hyperinsulinism, a rare endocrine disorder causing excessive insulin production and resulting hypoglycemia. Rezolute's pipeline includes drug candidates designed to improve patient outcomes while reducing treatment burdens. The company engages in research, development, and clinical trials to advance its therapies and collaborates with medical communities and patient groups to support its objectives. Revenue and value creation depend largely on successful product development and regulatory approvals.